Paushak

Which are the latest news on Paushak?

Why is Paushak Ltd falling/rising?

As of 05-Sep, Paushak Ltd's stock price is Rs 784.95, down 2.42% due to recent underperformance and a drop to an intraday low of Rs 781.55. Despite a year-to-date increase of 32.25%, today's decline reflects weaker relative performance and ongoing price pressure.

As of 05-Sep, Paushak Ltd's stock price is currently at Rs 784.95, reflecting a decrease of Rs 19.5, or 2.42%. This decline can be attributed to several factors observed in the recent performance metrics. <BR><BR>Today, the stock underperformed its sector by 3.59%, indicating weaker relative performance compared to its peers. Additionally, the stock reached an intraday low of Rs 781.55, which represents a drop of 2.85% from the previous levels. The trading activity also suggests a trend towards lower prices, as the weighted average price indicates that more volume was traded closer to this low price.<BR><BR>Despite these negative indicators, it is worth noting that Paushak Ltd has shown positive performance over longer periods, with a year-to-date increase of 32.25%, significantly outperforming the Sensex, which has declined by 10.21% in the same timeframe. Furthermore, the stock is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically suggests a bullish trend. <BR><BR>However, the immediate price drop and underperformance today are likely contributing to the current decline in stock price. Rising investor participation, as evidenced by a 41.97% increase in delivery volume against the 5-day average, may indicate interest in the stock, but it has not yet translated into upward price movement. Overall, the combination of today's underperformance and the recent price drop are the primary reasons for the current decline in Paushak Ltd's stock price.

Who are in the management team of Paushak?

The management team of Paushak includes Chirayu R Amin (Chairman), Udit C Amin, Amit M Goradia, Vijay H Gandhi, Abhijit A Joshi (CEO), Atul Patel, Roopa Patel, and Tushar Arvindbhai Shah, combining both executive and independent directors.

The management team of Paushak includes the following individuals:<BR><BR>1. **Chirayu R Amin** - Chairman (Non-Executive)<BR>2. **Udit C Amin** - Non-Executive & Non-Independent Director<BR>3. **Amit M Goradia** - Non-Executive & Independent Director<BR>4. **Vijay H Gandhi** - Non-Executive & Independent Director<BR>5. **Abhijit A Joshi** - Whole Time Director & CEO<BR>6. **Atul Patel** - Non-Executive & Independent Director<BR>7. **Roopa Patel** - Independent Director<BR>8. **Tushar Arvindbhai Shah** - Independent Director<BR><BR>This team brings a mix of executive and non-executive leadership to the company.

What does Paushak do?

Paushak Ltd is India's largest manufacturer of phosgene-based specialty chemicals, part of the Alembic Group, with a market cap of INR 1,907 Cr and reported net sales of 84 Cr and net profit of 15 Cr for June 2026. The company operates in the micro-cap segment of the specialty chemicals industry.

Overview:<BR>Paushak Ltd is India's largest manufacturer of phosgene-based specialty chemicals, operating within the micro-cap segment of the specialty chemicals industry.<BR><BR>History:<BR>Paushak Limited was established in May 1972 and is part of the Alembic Group, which has a legacy of over 115 years. The latest quarterly results reported net sales and net profit for the period ending June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 84 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 15 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 1,907 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 44.00 <BR>Industry P/E: 26 <BR>Dividend Yield: 0.32% <BR>Debt Equity: 0.10 <BR>Return on Equity: 8.63% <BR>Price to Book: 3.93 <BR><BR>Contact Details:<BR>Address: 5th Floor Administration Buidg, Alembic Road Vadodara Gujarat : 390003 <BR>Tel: 91-265-2280550 <BR>Email: paushak.investors@alembic.co.in <BR>Website: http://www.paushak.com

Who are the peers of the Paushak?

Paushak's peers include DDev Plastiks, NOCIL, Rossari Biotech, S H Kelkar & Co., Camlin Fine, Vidhi Specialty, Indokem, Titan Biotech, and Oriental Aromat. Titan Biotech has the highest 1-year return at 160.06%, while Paushak's return is 1.39%.

Peers: The peers of Paushak are DDev Plastiks, NOCIL, Rossari Biotech, S H Kelkar & Co., Camlin Fine, Vidhi Specialty, Indokem, Titan Biotech, and Oriental Aromat.<BR><BR>Quality Snapshot: Excellent management risk is observed at DDev Plastiks, Rossari Biotech, and Titan Biotech, while Average management risk is found at NOCIL, S H Kelkar & Co., Paushak, Vidhi Specialty, and Oriental Aromat. Below Average management risk is noted at Camlin Fine and Indokem. In terms of Growth, Good growth is seen at DDev Plastiks, Average growth at Rossari Biotech and Nitta Gelatin, while Below Average growth is reported for NOCIL, S H Kelkar & Co., Paushak, Camlin Fine, Vidhi Specialty, Indokem, Titan Biotech, and Oriental Aromat. Excellent capital structure is present at DDev Plastiks, NOCIL, Rossari Biotech, Paushak, Vidhi Specialty, Titan Biotech, and Nitta Gelatin, while Average capital structure is found at S H Kelkar & Co. and Below Average at Camlin Fine, Indokem, and Oriental Aromat.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Titan Biotech at 160.06%, while the lowest is Camlin Fine at -49.11%. Paushak's own 1-year return is 1.39%, which is significantly higher than Camlin Fine's but lower than Titan Biotech's. Additionally, the peers with negative six-month returns include Rossari Biotech and Camlin Fine.

How big is Paushak?

As of 31st August, Paushak Ltd has a market capitalization of 1,907.00 Cr, with recent net sales of 246.27 Cr and a net profit of 42.39 Cr. Shareholder's funds are 491.12 Cr, and total assets amount to 659.94 Cr as of March 2026.

As of 31st August, Paushak Ltd has a market capitalization of 1,907.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Paushak reported Net Sales of 246.27 Cr and a Net Profit of 42.39 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, with Shareholder's Funds amounting to 491.12 Cr and Total Assets of 659.94 Cr.

Should I buy, sell or hold Paushak Ltd?

Are Paushak Ltd latest results good or bad?

Paushak Ltd's latest results show strong revenue growth of 51.52% quarter-on-quarter, reaching ₹83.55 crores, but profitability concerns arise with a net profit decline of 20.70% year-on-year and a reduced PAT margin of 18.07%. While sales are robust, the company faces challenges with rising costs and operational efficiency that could impact future growth.

Paushak Ltd's latest results present a mixed picture. On one hand, the company achieved a significant revenue surge of 51.52% quarter-on-quarter, reaching ₹83.55 crores, which is the highest quarterly sales in its recent history. This strong top-line growth indicates robust demand for its specialty chemicals, particularly in isocyanates, chloroformates, and carbamates.<BR><BR>However, this impressive revenue growth comes with notable concerns regarding profitability. The net profit for the quarter was ₹15.10 crores, reflecting a quarter-on-quarter increase of 25.49%, but a year-on-year decline of 20.70%. Furthermore, the profit after tax (PAT) margin has contracted sharply to 18.07%, down from 21.53% a year ago, indicating that rising input costs or operational inefficiencies are impacting the bottom line.<BR><BR>Additionally, while the operating margin improved slightly to 30.70% from the previous quarter, it is still down from 31.94% a year earlier. The company's return on equity (ROE) and return on capital employed (ROCE) metrics are also below industry averages, raising concerns about capital efficiency.<BR><BR>Overall, while the revenue performance is strong, the simultaneous margin compression and declining profitability metrics suggest that the company's growth may not be sustainable without addressing these operational challenges. Investors may need to weigh these factors carefully when considering the company's future prospects.

When is the next results date for Paushak Ltd?

The next results date for Paushak Ltd is 30 July 2026.

The next results date for Paushak Ltd is scheduled for 30 July 2026.

Is Paushak technically bullish or bearish?

As of December 1, 2025, the trend is mildly bullish with daily moving averages supporting this view, but caution is advised due to bearish signals from the weekly MACD and Bollinger Bands, despite some bullish indicators in the monthly MACD.

As of 1 December 2025, the technical trend has changed from sideways to mildly bullish. The current stance is mildly bullish, supported by the daily moving averages indicating a positive trend. However, the weekly MACD remains bearish, which suggests caution. The monthly MACD is mildly bullish, providing some support for the overall bullish outlook. The Bollinger Bands are bearish across both weekly and monthly time frames, indicating potential volatility. The KST shows a mixed picture with weekly mildly bearish and monthly mildly bullish readings. Overall, while there are some bullish indicators, the presence of bearish signals in the MACD and Bollinger Bands suggests a cautious approach.

How has been the historical performance of Paushak?

Paushak's historical performance shows a slight decline in net sales and operating profit from Mar'23 to Mar'25, with profit after tax decreasing to 49.38 Cr. Despite increased total assets, rising liabilities and decreased cash flow from operating activities indicate potential liquidity challenges.

Answer:<BR>The historical performance of Paushak shows a fluctuating trend in net sales, with a peak of 212.35 Cr in Mar'23, followed by a slight decline to 210.95 Cr in Mar'25. The total operating income has mirrored this trend, reaching 212.35 Cr in Mar'23 and settling at 210.95 Cr in Mar'25. Raw material costs have decreased from 48.24 Cr in Mar'23 to 43.43 Cr in Mar'25, while employee costs have risen from 26.77 Cr in Mar'23 to 35.48 Cr in Mar'25. Operating profit (PBDIT) has shown a decline from 84.24 Cr in Mar'23 to 73.89 Cr in Mar'25, with the operating profit margin decreasing from 35.41% to 28.28%. Profit before tax also decreased from 72.22 Cr in Mar'23 to 58.78 Cr in Mar'25, leading to a profit after tax of 49.38 Cr in Mar'25, down from 54.01 Cr in Mar'23. The company's total assets have increased from 414.74 Cr in Mar'23 to 571.98 Cr in Mar'25, while total liabilities have also risen from 481.35 Cr to 571.98 Cr in the same period. Cash flow from operating activities has decreased from 56.00 Cr in Mar'24 to 37.00 Cr in Mar'25, indicating a tightening cash position.<BR><BR>Breakdown:<BR>Paushak's net sales have shown a slight decline from 212.35 Cr in Mar'23 to 210.95 Cr in Mar'25, while total operating income has followed a similar pattern. Raw material costs decreased significantly, contributing to a lower operating profit (PBDIT) of 73.89 Cr in Mar'25 compared to 84.24 Cr in Mar'23. The operating profit margin has also decreased, reflecting rising employee costs. Profit before tax has decreased to 58.78 Cr in Mar'25 from 72.22 Cr in Mar'23, resulting in a profit after tax of 49.38 Cr. The company's total assets have increased substantially, indicating growth, but total liabilities have risen correspondingly, suggesting increased financial obligations. Cash flow from operating activities has decreased, highlighting potential liquidity challenges.

Who are the top shareholders of the Paushak?

The top shareholders of Paushak include Nirayu Limited with 41.15%, individual investors with 25.23%, and three foreign institutional investors holding 0.01%. There are no mutual funds or public shareholders among the top holdings.

The top shareholders of Paushak include the promoters, with Nirayu Limited holding the largest stake at 41.15%. Additionally, individual investors collectively own 25.23% of the company. There are also three foreign institutional investors (FIIs) that hold a very small percentage, specifically 0.01%. Notably, there are no mutual funds currently invested in Paushak, and there are no public shareholders listed among the top holdings.

Is Paushak overvalued or undervalued?

As of April 9, 2020, Paushak is considered very expensive and overvalued with a PE Ratio of 27.25, elevated compared to industry norms, and has underperformed against the Sensex, declining 11.69% year-to-date while the Sensex gained 5.63%.

As of 9 April 2020, the valuation grade for Paushak has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios supporting this conclusion include a PE Ratio of 27.25, an EV to EBITDA of 22.83, and a Price to Book Value of 2.89, all of which are elevated compared to industry norms.<BR><BR>In comparison to its peers, Paushak's valuation stands out as particularly high; for instance, P I Industries has a PE Ratio of 35.59 and Bayer CropScience has a PE Ratio of 43.48, both of which are in the very expensive category, yet they still exceed Paushak's valuation metrics. Additionally, UPL, categorized as attractive, has a PE Ratio of 38.74, further highlighting the disparity. Notably, Paushak has underperformed against the Sensex over various time frames, including a year-to-date decline of 11.69% compared to the Sensex's gain of 5.63%, reinforcing the view that the stock is overvalued.

Has Paushak declared dividend?

Paushak Ltd has declared a 200% dividend, amounting to ₹20 per share, with an ex-date of July 26, 2024. While the company shows a positive 5-year total return of 104.37%, shorter-term returns have been negative, reflecting mixed performance overall.

Paushak Ltd has declared a 200% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 20<BR>- Ex-date: 26 Jul 24<BR><BR>Dividend Yield: 0.48%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -18.16%, with a dividend return of 0%, resulting in a total return of -18.16%.<BR><BR>Over the past year, the price return was -14.15%, with a dividend return of 0.36%, leading to a total return of -13.79%.<BR><BR>In the 2-year period, the price return was -35.43%, while the dividend return was 0.53%, culminating in a total return of -34.9%.<BR><BR>For the 3-year period, the price return was -53.5%, with a dividend return of 0.56%, resulting in a total return of -52.94%.<BR><BR>In the last 4 years, the price return was -43.08%, and the dividend return was 0.79%, leading to a total return of -42.29%.<BR><BR>Over the 5-year period, the price return was 102.04%, with a dividend return of 2.33%, resulting in a total return of 104.37%.<BR><BR>Overall, while Paushak Ltd has declared a significant dividend, the total returns over various periods show a mixed performance, with substantial losses in the shorter terms but a positive return over the longer 5-year period.